Alumis (ALMS) Revenue (2025 - 2026)

Alumis (ALMS) posted quarterly Revenue of $1.9 million for Q4 2025, down 6.63% quarter-over-quarter from $2.1 million in Q3 2025.

Alumis (ALMS) Revenue (2025 - 2026) Analysis & Trends

Alumis (ALMS) has reported Revenue for 1 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.

In Q4 2025, Revenue changed N/A year-over-year to $1.9 million; the TTM figure through Dec 2025 stood at $24.1 million (changed N/A YoY), while the FY2025 annual figure was $24.0 million, changed N/A from the prior year.
Revenue declined to $1.9 million in Q4 2025 per ALMS's latest filing, from $2.1 million in the prior quarter.
Across five years, Revenue topped out at $17.4 million in Q1 2025 and bottomed at $1.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Alumis	3.25 Bn	2.75 Bn	-	1.66 Mn

Download Data